EIP Pharma, LLC   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2014)

Organization Overview

First Clinical Trial
2015
NCT02423200
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

EIP Pharma | EIP Pharma, LLC

Active Ingredients

Drugs in Phase 2 Trials (2)

neflamapimod (3 trials)

vx-745 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cognitive Dysfunction (Phase 2)

Dementia (Phase 2)

Huntington Disease (Phase 2)

Lewy Body Disease (Phase 2)

Plaque, Amyloid (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2